Drug Profile
Research programme: antibacterials - Affibody/Creative Antibiotics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Affibody; Creative Antibiotics
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Gram-negative-infections in Sweden
- 17 Jul 2012 Affibody and Creative antibiotics agree to collaborate on the development of antibacterials in Sweden for Gram-negative infections ,,
- 02 Feb 2012 Early research in Gram-negative infections in Sweden (unspecified route)